Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Anxiolytic Drugs: Overview01:26

Anxiolytic Drugs: Overview

Anxiolytic drugs are vital in managing anxiety disorders by effectively alleviating symptoms such as excessive fear, tachycardia, and tremors. There are several classes of anxiolytic medications, each with unique mechanisms of action and potential side effects.
Primary Types of Anxiolytic Drugs
1. Benzodiazepines:
Benzodiazepines bind to the GABA-A receptor in the brain, enhancing GABA's interaction. This action reduces neurotransmission, effectively blocking anxiety-associated limbic circuitry.
Therapeutic Drug Monitoring: Overview and Classification01:16

Therapeutic Drug Monitoring: Overview and Classification

Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Evaluation of antibacterial efficiency of <i>Trapa natans</i> modified glass ionomer cement: An in vitro study.

Journal of Taibah University Medical Sciences·2026
Same authorSame journal

Drugs and polymer based local delivery systems in the treatment of periodontal diseases.

Profiles of drug substances, excipients, and related methodology·2026
Same author

Riboflavin-sensitized photoinduced degradation of donepezil hydrochloride: kinetic and computational insights for pharmaceutical formulation.

RSC advances·2025
Same author

Cyclodextrin-assisted photostabilization of 5-fluorouracil: a combined kinetic and computational investigation.

RSC advances·2025
Same author

Correction: High-performance liquid chromatographic method for determination of voriconazole in pure and gel formulation.

PloS one·2025
Same author

PEGylated chitosan xerogels for localized periodontal therapy: design, characterization, and drug release.

Scientific reports·2025
Same journal

Preface.

Profiles of drug substances, excipients, and related methodology·2026
Same journal

Rosuvastatin calcium: A comprehensive profile.

Profiles of drug substances, excipients, and related methodology·2026
Same journal

Kinetic exclusion assay technology: Theory, experimental aspects, and applications in concentration measurements across diverse fields.

Profiles of drug substances, excipients, and related methodology·2026
Same journal

Perindopril: A comprehensive profile.

Profiles of drug substances, excipients, and related methodology·2026
Same journal

Ferulic acid: A comprehensive profile.

Profiles of drug substances, excipients, and related methodology·2026
関連記事をすべて見る

関連する実験動画

Updated: May 12, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

ヴォルティオキセチン:包括的なプロフィール

Zubair Anwar1, Saba Sabir1, Muhammad Ali Sheraz1

  • 1Baqai Institute of Pharmaceutical Sciences, Baqai Medical University, Karachi, Pakistan.

Profiles of drug substances, excipients, and related methodology
|February 19, 2026
PubMed
まとめ
この要約は機械生成です。

ヴォルティオキセチンは,メジャーうつ病の治療に使用される新しい抗うつ薬です. セロトニントランスポーターを阻害し,様々なセロトニン受容体を調節することで作用し,治療に多式アプローチを提供します.

キーワード:
有害および有毒な影響 有害および有毒な影響メジャーうつ病障害 メジャーうつ病障害分析方法 分析方法について安定性と劣化についてヴォルティオキセチンは,ヴォルティオキセチンの

さらに関連する動画

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

関連する実験動画

Last Updated: May 12, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder
04:33

Association Between Sleep Quality and Cognitive Symptoms in Patients with Major Depressive Disorder

Published on: April 26, 2024

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model
08:15

Network Pharmacology and Validation of the Antidepressant Mechanisms of Qiangzhifang in a Chronic Restraint Stress-induced Depression Rat Model

Published on: June 6, 2025

科学分野:

  • 薬理学 薬理学とは
  • 薬用化学 薬用化学について
  • 神経科学は神経科学である.

背景:

  • ヴォルティオキセチン (VX) は,マルチモデルの抗うつ薬である.
  • それはセロトニン調節器およびシミュレータ (SMS) として分類されています.
  • VXはメジャーうつ病 (MDD) の治療に広く処方されています.

研究 の 目的:

  • ヴォルティオキセチンの包括的なレビューを提供するために.
  • その記述,合成,物理的特性,分析方法などをカバーする.
  • 詳細にその薬理学,治療用途,および副作用について説明します.

主な方法:

  • 文献レビューとデータ合成.
  • ヴォルティオキセチンの性質と効果に関する既存の研究の分析.
  • 分類,分類,不純物,合成,物理特性,分析方法,安定性,分解,薬理学,毒理学に関する情報をまとめました.

主要な成果:

  • VXはマルチモダルの作用メカニズムを示しています.
  • セロトニントランスポーター (SERT) を阻害する.
  • VXは,いくつかのセロトニン受容体 (5-HT1A,5-HT1B,5-HT3,5-HT1D,5-HT7) を調節する.

結論:

  • このモノグラフィは,ヴォルティオキセチンの詳細な概要を提供します.
  • VXの化学的,物理的,薬理的,臨床的な側面に関する情報を合成しています.
  • このレビューは,MDDの治療におけるVortioxetineの役割を理解するためのリソースとして機能します.